Drug intelligence / Profile preview

Bladexa

Development stage: Unknown
Lead developer: Kéri Pharma
Modality: Small Molecules
Administration: Oral

Overview

Bladexa is an oral dietary supplement developed and marketed by the Hungarian pharmaceutical company Kéri Pharma. It is formulated as film-coated tablets containing a combination of six active ingredients specifically selected to support urological health and the maintenance of healthy mucous membranes. As a product within Kéri Pharma's urology platform, it is positioned as a food supplement intended to promote normal physiological function of the urinary tract and mucosal surfaces rather than as a prescription pharmaceutical for acute disease treatment.

Brand names: Bladexa

Beyond the preview

Go deeper on Bladexa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bladexa.

Explore the full profile